Efficacy and safety of everolimus in de novo heart transplant recipients.

Trial Profile

Efficacy and safety of everolimus in de novo heart transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2015

At a glance

  • Drugs Ciclosporin; Everolimus; Mycophenolate mofetil
  • Indications Heart transplant rejection; Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2009 Primary endpoint 'Creatinine clearance' has not been met; results published in 'Transplantation'.
    • 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top